140 related articles for article (PubMed ID: 33457057)
1. Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without
Garcia A; Frahm C; Jeter JM; Abraham I; Chambers SK; Cragun JM; McBride A
J Adv Pract Oncol; 2019 Jul; 10(5):428-439. PubMed ID: 33457057
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Giannone G; Scotto G; Katsaros D; De Giorgi U; Farolfi A; Borella F; Cosma S; Ferrero A; Mangiacotti S; Villa M; Tuninetti V; Ghisoni E; Turinetto M; Mittica G; Gemmiti S; Zavallone L; Aglietta M; Pasini B; Di Maio M; Valabrega G
Gynecol Oncol; 2021 Jul; 162(1):80-87. PubMed ID: 33896588
[TBL] [Abstract][Full Text] [Related]
3. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
6. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
Rolfe M; Gegeckas C; Turner S; Orr JW
J Oncol Pharm Pract; 2021 Oct; 27(7):1704-1709. PubMed ID: 33100178
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
9. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
10. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
11. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
12. [Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].
Rezáč A; Jílek P; Rezáčová V; Skapinec P; Sedláková I; Tošner J; Spaček J
Ceska Gynekol; 2013 Dec; 78(6):514-21. PubMed ID: 24372428
[TBL] [Abstract][Full Text] [Related]
13. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Altwerger G; Florsheim EB; Menderes G; Black J; Schwab C; Gressel GM; Nelson WK; Carusillo N; Passante T; Huang G; Litkouhi B; Azodi M; Silasi DA; Santin A; Schwartz PE; Ratner ES
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2449-2456. PubMed ID: 30255380
[TBL] [Abstract][Full Text] [Related]
14. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
15. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
16. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
18. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Marchetti C; Tudisco R; Salutari V; Pietragalla A; Scambia G; Fagotti A
Int J Gynecol Cancer; 2021 Aug; 31(8):1175-1178. PubMed ID: 34131041
[TBL] [Abstract][Full Text] [Related]
20.
Manchana T; Phoolcharoen N; Tantbirojn P
Gynecol Oncol Rep; 2019 Aug; 29():102-105. PubMed ID: 31467961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
